Study authors suggested health systems with limited surgical capacity prioritize metabolic bariatric surgery for patients demonstrating clinical obesity-related organ dysfunction.

Overview Debates Related claims Topics Sources

Study authors proposed bariatric surgery serve as a first-line treatment for clinical obesity, but as a second-line risk-reduction option for preclinical obesity as pharmacotherapy expands.

Clinical obesity prevalence among metabolic bariatric surgery candidates varied across international centers, ranging from 62.7% in the Brazilian cohort to 79.3% in the United Kingdom cohort.

Mean body mass index and distribution across BMI categories (<40, 40-49, and ≥50) did not differ significantly between clinical and preclinical obesity groups within surgical centers.

Study authors noted bariatric surgery in clinical obesity may offer faster economic returns due to reduced post-operative complications, decreased medication use, and fewer hospitalizations.

Bariatric surgery patients with clinical obesity lost modestly less weight post-surgery, trailing preclinical obesity patients by 2 to 4 percentage points in several study cohorts at 12 and 24 months.

Study authors stated bariatric surgery for preclinical obesity should be evaluated as a preventive intervention with longer time horizons and distinct cost-effectiveness thresholds.

A Lancet Diabetes & Endocrinology Commission led by Dr. Francesco Rubino in January 2025 proposed separating clinical obesity from preclinical obesity based on organ dysfunction.

Investigators evaluated 2,316 adult gastric bypass and sleeve gastrectomy patients from centers in London, Barcelona, Lille, and São Paulo using the Lancet Diabetes & Endocrinology framework.

Patients with clinical obesity experienced higher baseline American Society of Anesthesiologists surgical risk classifications across all four international study cohorts compared to preclinical obesity patients.

In the French cohort analyzed in the study, major 30-day post-operative complications occurred in 4.0% of clinical obesity patients compared to 1.1% of preclinical obesity patients.

A JAMA Network Open study of 2,316 adults undergoing metabolic bariatric surgery between 2014 and 2025 found that 73.8% (1,709 patients) met criteria for clinical obesity.

Findings from the Lancet Diabetes & Endocrinology meta-analysis and prior 2023 research indicated that replacing red meat with nuts, legumes, or dairy significantly lowers the risk of developing type 2 diabetes.

Elevated liver ENT1 expression in patients with early-stage MASLD was associated with higher insulin levels and elevated HOMA-IR insulin resistance scores.

In animal models, ENT1 deficiency led to improved glucose tolerance and increased insulin sensitivity across overall body metabolism.

Mice deficient in ENT1 exhibited reduced liver adenosine levels and protection against inflammation, fibrosis, and excessive liver fat accumulation.

The NutriNet-Santé study found that consumption of Neu5Gc derived from dairy products was not associated with an increased risk of type 2 diabetes.

A 2023 study covering over 200,000 participants found that high overall red meat consumption was associated with a 62% higher risk of developing type 2 diabetes.

A September 2024 federated meta-analysis in The Lancet Diabetes & Endocrinology evaluating adults across 31 global cohorts identified over 107,000 incident cases of type 2 diabetes.

Researchers at Université Sorbonne Paris Nord estimated that obesity accounted for approximately 13% of the statistical relationship between meat-derived Neu5Gc consumption and type 2 diabetes risk.

A NutriNet-Santé observational study presented at the Annual Meeting of The European Association for the Study of Diabetes in Milan linked high intake of meat-derived N-glycolylneuraminic acid (Neu5Gc) sugar to a 63% higher risk of developing type 2 diabetes.